PFIPlatinum-Free Interval Assessment
Historical Context
The 6-month threshold remains the standard for clinical trial stratification and therapy selection. However, modern oncology recognizes PFI as a continuum, where longer intervals correlate with higher response rates to subsequent platinum-based therapy.
Therapeutic Category
Management Strategy
Sensitive recurrence (> 6-12 months). Re-challenge with platinum-based doublet is the standard of care.
Verified
Last Review: 2026
| Interval (Months) | Classification | Therapeutic Implication |
|---|---|---|
| < 1 month (or progression on therapy) | Platinum-Refractory | Dismal prognosis. Platinum retreatment is futile. Use non-platinum agents (Doxil, Paclitaxel) or clinical trials. |
| 1 - 6 months | Platinum-Resistant | Low response to platinum (~10%). Treat with single-agent non-platinum therapy + Bevacizumab. |
| 6 - 12 months | Partially Platinum-Sensitive | Response to platinum ~30%. Can retreat with platinum-doublets, often utilizing carboplatin/pegylated liposomal doxorubicin. |
| > 12 months | Highly Platinum-Sensitive | High response to platinum (>50%). Rechallenge with platinum-doublet is the standard of care. |
Pujade-Lauraine E et al. • Seminars in Oncology. 2000;27(3 Suppl 7):11-4
Last Comprehensive Review: 2026
Clinical Context
We think this has broad domain relevance to Platinum-Free Interval (PFI).
Clinical Context
We think this might be relevant to the clinical guidance for Platinum-Free Interval (PFI).
Clinical Context
We think this might be relevant to the clinical guidance for Platinum-Free Interval (PFI).